Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market

Published: Monday, April 22, 2013
Last Updated: Sunday, April 21, 2013
Bookmark and Share
Participants need to focus on product customization, ease-of-use and reliability.

Cardiovascular disease (CVD) is the main cause of death in the EU, killing over 2 million people annually and costing the economy nearly €192 billion. Prevention, through constant monitoring of heart health, is seen as the best way to tackle this high death rate.

The most accurate way of monitoring heart health is through cardiac marker testing. Regular monitoring of cardiac health through brain natriuretic peptide (BNP) testing is being practiced across Europe, thereby boosting the cardiac marker testing market.

New analysis from Frost & Sullivan (http://www.healthcare.frost.com), Analysis of European Cardiac Biomarkers Diagnostics Market, finds that the market earned revenues of about $607.9 million in 2011 and estimates this to double to reach $1,216.0 million in 2018.

The research covers acute myocardial infarction (AMI) and congestive heart failure (CHF) biomarkers diagnostics.

The increasing role of cardiac markers in patient triaging is further boosting market expansion. Effective implementation of cardiac markers can enable decreased bed occupancy, reduced hospital costs and physician time.

“Cardiac markers rank among the best available tools to assess the patient’s status,” notes Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. “For instance, in cases where a test is positive for certain markers, especially cardiac troponin, this would indicate a heart attack. Subsequently, the appropriate treatments and interventions could be administered.”

Due to the urgent nature of myocardial infarction, commonly known as a heart attack, healthcare practitioners have to obtain rapid results for immediate diagnosis and treatment. This need for quick turnaround times has fuelled interest in point-of-care (POC) cardiac testing.

As these trends accelerate market development, saturation will pose a key restraint, especially for the troponin testing segment.

“The troponin testing segment, which now constitutes about a third of the cardiac marker testing market, has reached saturation,” explained Sashidhar. “It is expected to grow slowly, especially in lab-based testing, with growth likely to be mainly through POC testing.”

To sustain market momentum, participants need to develop customized solutions. Multi-menu options for cardiac tests and products that meet market needs, paralleled by alliances with pharmaceutical companies to develop better targeted, therapy-oriented solutions, will keep the market on a growth trajectory.

“Companies need to develop monitoring systems with sufficient product differentiation features to stay competitive,” concluded Sashidhar. “Regardless of the test solution, ease-of-use and reliability will be essential to sustain growth.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Changing Phase of Biomarkers
Discover the current scenario and changing business models of the biomarkers field.
Monday, April 13, 2015
Gene Expression Profiling Drives Personalized Medicine Worldwide
Large amounts of information generated by gene expression profiling will increase implementation of data management tools.
Tuesday, June 10, 2014
Personalized Medicine Drives Uptake of Next-generation Sequencing in Europe
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years.
Saturday, May 31, 2014
Next Generation Sequencing on the European Growth Path
Next Generation Sequencers have found their way into labs and the global biomedical research community. 2010 has seen a serious uptake of Next Generation Sequencing technology, and today it is perceived as an indispensable tool for researchers.
Wednesday, January 26, 2011
Converging towards Integrated Healthcare: A Frost & Sullivan Think Tank on Megatrends Affecting the Healthcare Industry
A clear separation between Medical Devices, Healthcare Technologies and Life Sciences is increasingly difficult. Yet the convergence of all areas opens the door to a new era, enabling personalisation, targeted medicines, new drug delivery mechanisms, and virtual patient monitoring tools, while allowing a preventative approach to healthcare at the same time.
Friday, October 08, 2010
Frost & Sullivan: Finding Healthcare's 'Holy Grail'
Faced with escalating treatment costs and pressure to be affordable while searching for efficiency and better quality, hospitals are turning towards Health IT (HIT) for assistance where patient care is no longer the sole responsibility of doctors and nurses alone.
Friday, July 09, 2010
Scientific News
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
How to Unlock Inaccessible Genes
An international team of biologists has discovered how specialized enzymes remodel the extremely condensed genetic material in the nucleus of cells in order to control which genes can be used.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Mapping Regulatory Elements
Systematically searching DNA for regulatory elements indicates limits of previous thinking
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
Genome-Wide Study Yields Markers of Lithium Response
An international consortium of scientists has identified a stretch of chromosome that is associated with responsiveness to the mood-stabilizing medication lithium among patients with bipolar disorder.
A Cancer’s Surprise Origins, Caught in Action
First demonstration of a melanoma arising from a single cell.
Understanding the Mechanisms Blocking Cancer Cell Growth
DNA damage can lead to gene inactivation or deregulation and cause various diseases such as cancer; however, many DNA repair mechanisms allow cells to survive against such damage.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!